Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Publisher: La Merie Publishing
Pages: 53
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0052
Release Date: March of 2017

400.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV) as of March 2017.

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections among young children in the United States and worldwide. Most infants are infected before the age of one, and virtually everyone gets an RSV infection by the age of two. A prophylactic vaccine is not available and specific treatment is limited to the monoclonal antibody Synagis (palivizumb), a candidate for biosimilar conversion in the near future.

RSV infection in the pediatric and adult populations account for more than 300,000 hospitalizations per year in the U.S. In the developing world, RSV is responsible for 30 million cases of acute respiratory tract infection and 200,000 deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.

The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules, peptides and proteins targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Antibodies, Vaccines & Antivirals. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Table of Contents


RSV Antibodies:

  • Palivizumab Biosuperiors
  • Palivizumab Biosimilars

RSV Antivirals:

  • Small Molecule Therapeuticss
  • Other RSV Therapeutics

RSV Vaccines:

  • Live-Attenuated & Whole-Inactivated RSV Vaccines
  • Virus-Like Particle (VLP) RSV Vaccines
  • Subunit RSV Vaccines
  • DNA-/RNA-Based RSV Vaccines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top